These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25661195)

  • 1. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.
    Hastrup N; Khalilieh S; Dale DC; Hanson LG; Magnusson P; Tzontcheva A; Tseng J; Huyck S; Rosenberg E; Krogsgaard K
    Cytokine; 2015 Apr; 72(2):197-203. PubMed ID: 25661195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
    Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
    Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
    Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
    Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
    Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
    Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
    Nair P; Gaga M; Zervas E; Alagha K; Hargreave FE; O'Byrne PM; Stryszak P; Gann L; Sadeh J; Chanez P;
    Clin Exp Allergy; 2012 Jul; 42(7):1097-103. PubMed ID: 22702508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
    Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
    Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.
    Loken MR; Chu SC; Fritschle W; Kalnoski M; Wells DA
    Cytometry B Clin Cytom; 2009 Jan; 76(1):27-36. PubMed ID: 18548614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
    Miller BE; Mistry S; Smart K; Connolly P; Carpenter DC; Cooray H; Bloomer JC; Tal-Singer R; Lazaar AL
    BMC Pharmacol Toxicol; 2015 Jun; 16():18. PubMed ID: 26092545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
    Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.
    Moss RB; Mistry SJ; Konstan MW; Pilewski JM; Kerem E; Tal-Singer R; Lazaar AL;
    J Cyst Fibros; 2013 May; 12(3):241-8. PubMed ID: 22995323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
    De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
    Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of oral mucosal neutrophil counts to detect the onset and resolution of profound neutropenia following high-dose myelosuppressive chemotherapy.
    Akpek G; Knight RD; Wright DG
    Am J Hematol; 2003 Jan; 72(1):13-9. PubMed ID: 12508262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.
    Nicholson GC; Tennant RC; Carpenter DC; Sarau HM; Kon OM; Barnes PJ; Salmon M; Vessey RS; Tal-Singer R; Hansel TT
    Pulm Pharmacol Ther; 2007; 20(1):52-9. PubMed ID: 16406722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.
    Braber S; Overbeek SA; Koelink PJ; Henricks PA; Zaman GJ; Garssen J; Kraneveld AD; Folkerts G
    Eur J Pharmacol; 2011 Oct; 668(3):443-9. PubMed ID: 21458445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.